Form 4: Lexicon Pharma Exec Converts RSUs, Covers Taxes

Lexicon Pharmaceuticals SVP Rachel Martens converted restricted stock units into common stock and sold a portion to cover tax obligations.

Summary

• Rachel Yap Martens, SVP, Partnerships & Corp Strat at Lexicon Pharmaceuticals, Inc. (LXRX), reported a transaction on February 28, 2026.
• Martens acquired 67,090 shares of Common Stock through the conversion of Restricted Stock Units (RSUs).
• Concurrently, 35,826 shares of Common Stock were disposed of at a price of $1.47 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Martens beneficially owns 31,264 shares of Common Stock directly.
• Martens also beneficially owns 134,180 derivative securities in the form of Restricted Stock Units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine insider transaction related to executive compensation and tax obligations, rather than a discretionary buy or sell decision reflecting a change in company outlook.

Positives

• The conversion of 67,090 Restricted Stock Units into Common Stock indicates the vesting of previously granted equity compensation, representing a realized benefit for the executive.

Negatives

• A portion of the acquired shares (35,826 shares) was immediately sold to cover tax withholding obligations, reducing the executive's direct equity stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, such as the conversion of Restricted Stock Units and subsequent sale of shares for tax purposes, are common and typically reflect pre-planned compensation events rather than a change in market sentiment or a strategic move by the executive.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event for an executive, not indicative of broader company performance or strategic shifts.

Next Steps

• Future vesting of remaining Restricted Stock Units will occur on February 28 of each of the three years following the year of grant, for the remaining 134,180 derivative securities.

Key Dates

Keywords

Lexicon Pharmaceuticals, LXRX, Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Tax Withholding, Equity Compensation, Rachel Yap Martens